Key Takeaways:
Astrana Health Inc. (NASDAQ: ASTH) reported first-quarter revenue of $965.1 million, a 56 percent year-over-year increase that beat Wall Street estimates and sent shares up more than 6 percent.
"Our results increasingly reflect the advantages of the platform we have built and the way we are embedding AI across our platform," CEO Brandon Sim said in a statement.
The healthcare services company posted strong growth across key metrics, with performance bolstered by the expansion of its full-risk contracts and a rapidly integrating acquisition. Adjusted earnings per share of 74 cents beat consensus by nearly 14 percent.
The beat was driven by momentum in the company's value-based care model and the successful integration of its recent Prospect acquisition, which management said was progressing "ahead of schedule." Astrana's proprietary AI platform was credited with improving operating leverage, reducing provider payment cycle times by over 50 percent. The company's adjusted EBITDA grew 82 percent from the prior year to $66.3 million.
Following the report, Baird lifted its price target on the stock to $45 from $40, while Needham raised its target to $41 from $30. Both firms cited the strengthening story and margin upside from the company's AI-driven efficiencies and expansion into full-risk contracts, which now cover approximately 40 percent of the company's total membership.
The strong performance and accelerated integration signal that Astrana's strategy of combining technology with value-based care is yielding significant financial results. Investors will watch for continued margin expansion and membership growth in the company's second-quarter results, expected in August.
This article is for informational purposes only and does not constitute investment advice.
